Skip to content
To the full analysis

Mediclin stock: balance sheet and debt

MED.DE
$5.98Closing price of 12 Nov 2026MEQIRI Score 61 out of 100

Mediclin has a debt to equity ratio of 1.57 and an interest coverage of 1.9x.

Daily figure as of 13 Nov 2026

Debt / Equity
1.57
Interest coverage
1.9x
Current ratio
1.62
Cash & equivalents
$79.99M
Total assets
$974.79M
Equity ratio
28.4%
Goodwill
$9.79M
Plus intangible assets of $9.08M
Net debt
$353.1M

Total assets and equity ratio

How large the balance sheet of Mediclin AG is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$297.41M$60.72Mnot split out36.7%−$32.2M
2007$299.09M$51.2M$50.04M38.6%−$23.69M
2008$380.19M$60.69M$58.49M43.4%$41.72M
2009$369.86M$56.68M$54.39M47.1%$27.25M
2010$372.77M$59.37M$56.71M49.0%$43.97M
2011$364.38M$57.63M$55.47M50.4%$53.94M
2012$354.14M$56.43M$54.58M49.1%$58.01M
2013$346.69M$57.03M$54.66M48.6%$59.75M
2014$354.16M$56.01M$53.84M48.2%$38.13M
2015$365.04M$55.84M$53.73M51.3%$23.53M
2016$384.58M$57.82M$53.82M52.3%$11.59M
2017$408.47M$60.84M$54.11M50.3%$24.4M
2018$492.81M$62.76M$54.11M43.0%$41.3M
2019$994.8M$64.35M$54.58M21.2%$526.5M
2020$983.4M$64.32M$54.58M19.9%$428.31M
2021$976.5M$63.09M$55.26M20.8%$339.61M
2022$1.02B$61.54M$55.26M22.8%$459.45M
2023$975.68M$25.26M$18.49M22.3%$403.95M
2024$1B$27.39M$18.17M24.6%$395.11M
2025$974.79M$18.87M$9.79M28.4%$353.1M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$32.2M$109.08M$00
2007$23.69M$115.43M$00
2008$63.59M$164.93M$105.31M0.64
2009$64.85M$174.26M$92.1M0.53
2010$53.14M$182.75M$97.11M0.53
2011$45.8M$183.45M$99.75M0.54
2012$25.42M$174.07M$83.43M0.48
2013$14.65M$168.87M$74.4M0.44
2014$29.2M$171.02M$67.32M0.39
2015$36.26M$187.81M$59.79M0.32
2016$50.59M$201.55M$62.18M0.31
2017$35.95M$205.59M$60.35M0.29
2018$42.82M$212.32M$84.12M0.4
2019$41.28M$211.64M$567.78M2.69
2020$111.29M$196.31M$539.61M2.75
2021$147.91M$203.09M$487.52M2.4
2022$97.56M$231.82M$557.01M2.4
2023$127.75M$217.1M$531.69M2.45
2024$119.19M$246.56M$514.3M2.08
2025$79.99M$275.86M$433.08M1.57

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Apr 2025)
  • Valuation signal Undervalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy